Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Drugs and Chemicals›Pancreatic Polypeptide
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Pancreatic Polypeptide

Drugs and Chemicals · NLM MeSH · updated 2026-10-31 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 5 min read

A 36-amino acid pancreatic hormone that is secreted mainly by endocrine cells found at the periphery of the islets OF langerhans and adjacent to cells containing somatostatin and glucagon.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (853 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

A 36-amino acid pancreatic hormone that is secreted mainly by endocrine cells found at the periphery of the islets OF langerhans and adjacent to cells containing somatostatin and glucagon. Pancreatic polypeptide (PP), when administered peripherally, can suppress gastric secretion, gastric emptying, pancreatic enzyme secretion, and appetite. A lack of pancreatic polypeptide (PP) has been associated with obesity in rats and mice.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Pancreatic Polypeptide Hormone; Pancreatic Polypeptide (PP); Pancreatic Prohormone.

Where it fits in the MeSH classification

Broader topics
Pancreatic Hormones; Neuropeptides

Related concepts

  • Islets
  • Langerhans
  • Somatostatin
  • Glucagon
  • Obesity

Research landscape

PubMed indexes 2,697 records tagged with the MeSH heading “Pancreatic Polypeptide” (counts retrieved 2026-10-31). 60 of them (2.2%) were published from 2020 onward, and the busiest period so far is through 1999 with 2,070 records.

Reviews account for 241 records (8.9%) and meta-analyses for 2. Randomized controlled trials number 133 (4.9%) as a share of all records on the topic.

PubMed records by publication periodthrough 1999: 2,070 records; 2000-2009: 355 records; 2010-2019: 212 records; 2020 onward: 60 records2,070through 19993552000-20092122010-2019602020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 19992,070
2000-2009355
2010-2019212
2020 onward60
Share of records by publication typeReviews: 8.9 percent; Meta-analyses: 0.1 percent; Randomized controlled trials: 4.9 percentReviews8.9% (241)Meta-analyses0.1% (2)Randomized controlled trials4.9% (133)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 2,697 PubMed records
TypeRecordsShare
Reviews2418.9%
Meta-analyses20.1%
Randomized controlled trials1334.9%

Method: PubMed query "Pancreatic Polypeptide"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.

Reading the evidence in drugs and chemicals

Studies of a chemical or drug can answer very different questions: what it is and how it behaves in cells and animals, how the body handles it, and whether it changes outcomes in people. Laboratory and animal findings often do not carry over to patients, and observational studies of exposures are confounded by who uses a substance and why. Nothing on this page is a recommendation to use, avoid, start or stop any substance or medicine; talk to a qualified clinician or pharmacist about your own situation. Check the dose, the species, the comparison group and whether a patient-relevant outcome was measured.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Pancreatic Ppy-expressing γ-cells display mixed phenotypic traits and the adaptive plasticity to engage insulin production
Perez-Frances M, van Gurp L, Abate MV, Cigliola V, Furuyama K, Bru-Tari E, et al.
2021Research article
Design not recorded in structured metadata
69cc by
PMID 34294685 · DOI · PMC8298494
Critical role of arcuate Y4 receptors and the melanocortin system in pancreatic polypeptide-induced reduction in food intake in mice
Lin S, Shi YC, Yulyaningsih E, Aljanova A, Zhang L, Macia L, et al.
2009Research article
Design not recorded in structured metadata
51cc by
PMID 20041129 · DOI · PMC2796177
Postprandial Effects of Blueberry (Vaccinium angustifolium) Consumption on Glucose Metabolism, Gastrointestinal Hormone Response, and Perceived Appetite in Healthy Adults: A Randomized, Placebo-Controlled Crossover Trial
Stote K, Corkum A, Sweeney M, Shakerley N, Kean T, Gottschall-Pass K
2019Randomized controlled trial
Design not recorded in structured metadata
33cc by
PMID 30669469 · DOI · PMC6356777
The Beneficial Impact of a Novel Pancreatic Polypeptide Analogue on Islet Cell Lineage
Zhu W, Tanday N, Flatt PR, Irwin N
2025Research article
Design not recorded in structured metadata
3cc by
PMID 40362452 · DOI · PMC12071604

Pancreatic Ppy-expressing γ-cells display mixed phenotypic traits and the adaptive plasticity to engage insulin production [1]

Research article Perez-Frances M, van Gurp L, Abate MV, Cigliola V, Furuyama K, Bru-Tari E, et al. · · 2021 · cited 69 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
The cellular identity of pancreatic polypeptide (Ppy)-expressing γ-cells, one of the rarest pancreatic islet cell-type, remains elusive.
Closing excerpt
In conclusion, we provide a comprehensive characterization of γ-cells and highlight their plasticity and therapeutic potential.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (157 words)

The cellular identity of pancreatic polypeptide (Ppy)-expressing γ-cells, one of the rarest pancreatic islet cell-type, remains elusive. Within islets, glucagon and somatostatin, released respectively from α- and δ-cells, modulate the secretion of insulin by β-cells. Dysregulation of insulin production raises blood glucose levels, leading to diabetes onset. Here, we present the genetic signature of human and mouse γ-cells. Using different approaches, we identified a set of genes and pathways defining their functional identity. We found that the γ-cell population is heterogeneous, with subsets of cells producing another hormone in addition to Ppy. These bihormonal cells share identity markers typical of the other islet cell-types. In mice, Ppy gene inactivation or conditional γ-cell ablation did not alter glycemia nor body weight. Interestingly, upon β-cell injury induction, γ-cells exhibited gene expression changes and some of them engaged insulin production, like α- and δ-cells. In conclusion, we provide a comprehensive characterization of γ-cells and highlight their plasticity and therapeutic potential.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 34294685 · DOI · PMC8298494

Critical role of arcuate Y4 receptors and the melanocortin system in pancreatic polypeptide-induced reduction in food intake in mice [2]

Research article Lin S, Shi YC, Yulyaningsih E, Aljanova A, Zhang L, Macia L, et al. · · 2009 · cited 51 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
BackgroundPancreatic polypeptide (PP) is a potent anti-obesity agent known to inhibit food intake in the absence of nausea, but the mechanism behind this process is unknown.
Closing excerpt
Conclusions/significanceTaken together, these findings show that PP reduces food intake predominantly via stimulation of the anorexigenic alpha-MSH signaling pathway, and that this effect is mediated by direct action on local Y4 receptors within the ARC, highlighting a potential novel avenue for the treatment of obesity.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (252 words)

BackgroundPancreatic polypeptide (PP) is a potent anti-obesity agent known to inhibit food intake in the absence of nausea, but the mechanism behind this process is unknown.Methodology/principal findingsHere we demonstrate that in response to i.p. injection of PP in wild type but not in Y4 receptor knockout mice, immunostaining for the neuronal activation marker c-Fos is induced specifically in neurons of the nucleus tractus solitarius and the area postrema in the brainstem, notably in cells also showing immunostaining for tyrosine hydroxylase. Importantly, strong c-Fos activation is also detected in the arcuate nucleus of the hypothalamus (ARC), particularly in neurons that co-express alpha melanocyte stimulating hormone (alpha-MSH), the anorexigenic product of the proopiomelanocortin (POMC) gene. Interestingly, other hypothalamic regions such as the paraventricular nucleus, the ventromedial nucleus and the lateral hypothalamic area also show c-Fos induction after PP injection. In addition to c-Fos activation, PP injection up-regulates POMC mRNA expression in the ARC as detected by in situ hybridization. These effects are a direct consequence of local Y4 signaling, since hypothalamus-specific conditional Y4 receptor knockout abolishes PP-induced ARC c-Fos activation and blocks the PP-induced increase in POMC mRNA expression. Additionally, the hypophagic effect of i.p. PP seen in wild type mice is completely absent in melanocortin 4 receptor knockout mice.Conclusions/significanceTaken together, these findings show that PP reduces food intake predominantly via stimulation of the anorexigenic alpha-MSH signaling pathway, and that this effect is mediated by direct action on local Y4 receptors within the ARC, highlighting a potential novel avenue for the treatment of obesity.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 20041129 · DOI · PMC2796177

Postprandial Effects of Blueberry (Vaccinium angustifolium) Consumption on Glucose Metabolism, Gastrointestinal Hormone Response, and Perceived Appetite in Healthy Adults: A Randomized, Placebo-Controlled Crossover Trial [3]

Randomized controlled trial Stote K, Corkum A, Sweeney M, Shakerley N, Kean T, Gottschall-Pass K · · 2019 · cited 33 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
The consumption of blueberries, as well as the phenolic compounds they contain, may alter metabolic processes related to type 2 diabetes.
Closing excerpt
Additional research is needed to determine whether blueberries and other flavonoid-rich foods reduce type 2 diabetes risk by modifying gastrointestinal hormones and perceived appetite.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (221 words)

The consumption of blueberries, as well as the phenolic compounds they contain, may alter metabolic processes related to type 2 diabetes. The study investigated the effects of adding 140 g of blueberries to a higher-carbohydrate breakfast meal on postprandial glucose metabolism, gastrointestinal hormone response, and perceived appetite. As part of a randomized crossover design study, 17 healthy adults consumed a standardized higher-carbohydrate breakfast along with 2 treatments: (1) 140 g (1 cup) of whole blueberries and (2) a placebo gel (matched for calories, sugars, and fiber of the whole blueberries). Each subject participated in two 2-h meal tests on separate visits ≥8 days apart. Venous blood samples and perceived appetite ratings using visual analog scales were obtained prior to and at 30, 60, 90, and 120 min after consuming the breakfast meals. Results show that glucose metabolism, several gastrointestinal hormones, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), peptide YY (PYY) concentrations and perceived appetite did not change significantly with blueberry consumption. However, pancreatic polypeptide (PP) concentrations were statistically significantly higher (p = 0.0367), and the concentrations were higher during 30, 60, 90, and 120 min after consumption of the blueberry breakfast meal than the placebo breakfast meal. Additional research is needed to determine whether blueberries and other flavonoid-rich foods reduce type 2 diabetes risk by modifying gastrointestinal hormones and perceived appetite.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 30669469 · DOI · PMC6356777

The Beneficial Impact of a Novel Pancreatic Polypeptide Analogue on Islet Cell Lineage [4]

Research article Zhu W, Tanday N, Flatt PR, Irwin N · · 2025 · cited 3 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
(Proline3)PP, or (P3)PP, is an enzymatically stable, neuropeptide Y4 receptor (NPY4R)-selective, pancreatic polypeptide (PP) analogue with established weight-lowering and pancreatic islet morphology benefits in obesity-diabetes.
Closing excerpt
Together these data reveal, for the first time, sustained NPY4R activation positively modulates beta-cell turnover, as well as islet cell plasticity, to help preserve pancreatic islet architecture following STZ-induced metabolic stress.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (223 words)

(Proline3)PP, or (P3)PP, is an enzymatically stable, neuropeptide Y4 receptor (NPY4R)-selective, pancreatic polypeptide (PP) analogue with established weight-lowering and pancreatic islet morphology benefits in obesity-diabetes. In the current study, we now investigate the impact of twice-daily (P3)PP administration (25 nmol/kg) for 11 days on islet cell lineage, using streptozotocin (STZ) diabetic Ins1Cre/+;Rosa26-eYFP and GluCreERT2;Rosa26-eYFP transgenic mice with enhanced yellow fluorescent protein (eYFP) labelling of beta-cell and alpha-cells, respectively. (P3)PP had no obvious impact on body weight or blood glucose levels in STZ-diabetic mice at the dose tested, but did return food intake towards control levels in Ins1Cre/+;Rosa26-eYFP mice. Notably, pancreatic insulin content was augmented by (P3)PP treatment in both Ins1Cre/+;Rosa26-eYFP and GluCreERT2;Rosa26-eYFP mice, alongside enhanced beta-cell area and reduced alpha-cell area. Beneficial (P3)PP-induced changes on islet morphology were consistently associated with decreased beta-cell apoptosis, while (P3)PP also augmented beta-cell proliferation in Ins1Cre/+;Rosa26-eYFP mice. Alpha-cell turnover rates were returned towards healthy control levels by (P3)PP intervention in both mouse models. In terms of islet cell lineage, increased transition of alpha- to beta-cells as well as decreased beta- to alpha-cell differentiation were shown to contribute towards the enhancement of beta-cell area in (P3)PP-treated mice. Together these data reveal, for the first time, sustained NPY4R activation positively modulates beta-cell turnover, as well as islet cell plasticity, to help preserve pancreatic islet architecture following STZ-induced metabolic stress.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 40362452 · DOI · PMC12071604

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis [5]
    Holzer P, Reichmann F, Farzi A · Neuropeptides · 2012 · cited 377 times (Europe PMC)
  • Research article Neuropeptide Y and neuropeptide Y receptor subtypes in brain and peripheral tissues [6]
    Dumont Y, Martel JC, Fournier A, St-Pierre S, Quirion R · Prog Neurobiol · 1992 · cited 288 times (Europe PMC)
  • Research article Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide [7]
    Larhammar D · Regul Pept · 1996 · cited 282 times (Europe PMC)
  • Research article Pancreatic polypeptide: a hormone under vagal control [8]
    Schwartz TW · Gastroenterology · 1983 · cited 254 times (Europe PMC)
  • Research article Distribution of pancreatic polypeptide and peptide YY [9]
    Ekblad E, Sundler F · Peptides · 2002 · cited 180 times (Europe PMC)
  • Research article Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide [10]
    Larhammar D · Regul Pept · 1996 · cited 173 times (Europe PMC)

References

  1. Perez-Frances M, van Gurp L, Abate MV, Cigliola V, Furuyama K, Bru-Tari E, et al.. Pancreatic Ppy-expressing γ-cells display mixed phenotypic traits and the adaptive plasticity to engage insulin production. . 2021. PMID 34294685 · DOI · PMC8298494
  2. Lin S, Shi YC, Yulyaningsih E, Aljanova A, Zhang L, Macia L, et al.. Critical role of arcuate Y4 receptors and the melanocortin system in pancreatic polypeptide-induced reduction in food intake in mice. . 2009. PMID 20041129 · DOI · PMC2796177
  3. Stote K, Corkum A, Sweeney M, Shakerley N, Kean T, Gottschall-Pass K. Postprandial Effects of Blueberry (Vaccinium angustifolium) Consumption on Glucose Metabolism, Gastrointestinal Hormone Response, and Perceived Appetite in Healthy Adults: A Randomized, Placebo-Controlled Crossover Trial. . 2019. PMID 30669469 · DOI · PMC6356777
  4. Zhu W, Tanday N, Flatt PR, Irwin N. The Beneficial Impact of a Novel Pancreatic Polypeptide Analogue on Islet Cell Lineage. . 2025. PMID 40362452 · DOI · PMC12071604
  5. Holzer P, Reichmann F, Farzi A. Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis. Neuropeptides. 2012. PMID 22979996 · DOI · PMC3516703
  6. Dumont Y, Martel JC, Fournier A, St-Pierre S, Quirion R. Neuropeptide Y and neuropeptide Y receptor subtypes in brain and peripheral tissues. Prog Neurobiol. 1992. PMID 1312243 · DOI
  7. Larhammar D. Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide. Regul Pept. 1996. PMID 8738876 · DOI
  8. Schwartz TW. Pancreatic polypeptide: a hormone under vagal control. Gastroenterology. 1983. PMID 6138294 · DOI
  9. Ekblad E, Sundler F. Distribution of pancreatic polypeptide and peptide YY. Peptides. 2002. PMID 11825640 · DOI
  10. Larhammar D. Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide. Regul Pept. 1996. PMID 8897639 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-31.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • SomatostatinDrugs and Chemicals
  • TirzepatideDrugs and Chemicals
  • Vasoactive Intestinal PeptideDrugs and Chemicals
  • Adrenocorticotropic HormoneDrugs and Chemicals
  • Growth Hormone-Releasing HormoneDrugs and Chemicals
  • Corticotropin-Releasing HormoneDrugs and Chemicals

All 546 articles in Drugs and Chemicals →

At a glance

2,697
PubMed records on this heading
2%
published since 2020
241
review articles
133
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-31; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • SomatostatinDrugs and Chemicals
  • TirzepatideDrugs and Chemicals
  • Vasoactive Intestinal PeptideDrugs and Chemicals
  • Adrenocorticotropic HormoneDrugs and Chemicals
  • Growth Hormone-Releasing HormoneDrugs and Chemicals

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support